The jointly run pilot clinical study is the first step in pioneering closed-loop opioid withdrawal detection and treatment 

The Medical University of South Carolina and UT Southwestern Medical Center join Spark Biomedical in Phase II clinical trial.

Spark Biomedical, Inc, the Hazelden Betty Ford Foundation, and Gaudenzia, Inc. Unite in Effort to Help Patients Reduce Relapse Risks and Sustain Recovery From Opioid Use Disorder

Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services (HHS), Eric D. Hargan, and his consulting firm, The Hargan Group, to help make novel withdrawal relief treatment more accessible and affordable for patients

First residential treatment center in the nation to offer The Sparrow™ Therapy System.

The First FDA Cleared, Drug-Free, Personalized Solution for Opioid Withdrawal Relief Now Available For Patient Use

A new class of opioid withdrawal treatment emerges in The Sparrow Therapy System — the first clinically proven, drug-free, needle-free, wearable neurostimulation solution for opioid withdrawal relief

Breakthrough Designation Helps Advance the Therapy Targeting a Significant Unmet Need in the Treatment of Neonatal Opioid Withdrawal Syndrome

Spark Biomedical, developer of the Sparrow ™ Therapy System — a discrete, wearable, over-the-ear, medical device designed for opioid withdrawal relief — announces the official formation of the company’s Medical Advisory Board on Pain Management.

FUNDS TO VALIDATE TRANSCUTANEOUS AURICULAR NEUROSTIMULATION FOR RELIEVING WITHDRAWAL SYMPTOMS IN INFANTS BORN WITH NEONATAL ABSTINENCE SYNDROME (NAS) Dallas, TX, October 18, 2019 — Spark Biomedical, Inc., a neurostimulation device company developing solutions for opioid withdrawal, received a $217,690 SBIR grant from the National Institutes of Health HEAL initiative. The grant (1R43DA050360-01) will be used to validate the use of neurostimulation to relieve withdrawal symptoms in infants born with neonatal abstinence syndrome (NAS).